Novavax NVAX Nuvaxovid sales — Total Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Novavax in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The official record: Novavax’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Novavax's nuvaxovid sales — total revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Novavax's nuvaxovid sales — total revenue?
- Novavax (NVAX) reported nuvaxovid sales — total revenue of $9.56M in Q1 2026.
- How has Novavax's nuvaxovid sales — total revenue changed year-over-year?
- Novavax's nuvaxovid sales — total revenue decreased by 98.4% year-over-year, from $608.03M to $9.56M.
- What is the long-term trend for Novavax's nuvaxovid sales — total revenue?
- Over 2 years (2023 to 2025), Novavax's nuvaxovid sales — total revenue has grown at a 8.5% compound annual growth rate (CAGR), from $531.39M to $625.18M.
- What does nuvaxovid sales — total revenue mean?
- This metric represents the total gross revenue generated from the commercial sale and distribution of the company's primary vaccine product. It serves as a key indicator of market adoption, product demand, and the effectiveness of the company's commercialization strategy within the infectious disease vaccine market. Tracking this figure allows investors to assess the revenue contribution of the core product line relative to the company's overall financial performance.